These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 23746182)

  • 21. Cost-effectiveness of pharmacist-participated warfarin therapy management in Thailand.
    Saokaew S; Permsuwan U; Chaiyakunapruk N; Nathisuwan S; Sukonthasarn A; Jeanpeerapong N
    Thromb Res; 2013 Oct; 132(4):437-43. PubMed ID: 24041634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective.
    Sorensen SV; Kansal AR; Connolly S; Peng S; Linnehan J; Bradley-Kennedy C; Plumb JM
    Thromb Haemost; 2011 May; 105(5):908-19. PubMed ID: 21431243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Universal versus genotype-guided use of direct oral anticoagulants in atrial fibrillation patients: a decision analysis.
    You JH
    Pharmacogenomics; 2015; 16(10):1089-100. PubMed ID: 26230572
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacoeconomic evaluation of warfarin pharmacogenomics.
    You JH
    Expert Opin Pharmacother; 2011 Feb; 12(3):435-41. PubMed ID: 21231897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacogenetic guided versus standard warfarin dosing for routine clinical care with its pharmacoeconomic impact: a randomized controlled clinical trial.
    Anand A; Hegde NC; Chhabra P; Purohit J; Kumar R; Gupta A; Lad DP; Mohindra R; Mehrotra S; Vijayvergiya R; Kumar B; Sharma V; Malhotra P; Ahluwalia J; Das R; Patil AN; Shafiq N; Malhotra S
    Ann Hematol; 2024 Jun; 103(6):2133-2144. PubMed ID: 38634917
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel oral anticoagulants versus warfarin therapy at various levels of anticoagulation control in atrial fibrillation--a cost-effectiveness analysis.
    You JH
    J Gen Intern Med; 2014 Mar; 29(3):438-46. PubMed ID: 24132628
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of rate control versus rhythm control for management of atrial fibrillation in patients with coexisting heart failure: a cost-effectiveness analysis.
    Perez A; Touchette DR; DiDomenico RJ; Stamos TD; Walton SM
    Pharmacotherapy; 2011 Jun; 31(6):552-65. PubMed ID: 21923439
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium.
    Wouters H; Thijs V; Annemans L
    J Med Econ; 2013; 16(3):407-14. PubMed ID: 23320796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy - a decision analysis.
    You JH; Chan FW; Wong RS; Cheng G
    Thromb Haemost; 2004 Sep; 92(3):590-7. PubMed ID: 15351856
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness.
    Kansal AR; Sharma M; Bradley-Kennedy C; Clemens A; Monz BU; Peng S; Roskell N; Sorensen SV
    Thromb Haemost; 2012 Oct; 108(4):672-82. PubMed ID: 22898892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing.
    Meckley LM; Gudgeon JM; Anderson JL; Williams MS; Veenstra DL
    Pharmacoeconomics; 2010; 28(1):61-74. PubMed ID: 20014877
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark.
    Langkilde LK; Bergholdt Asmussen M; Overgaard M
    J Med Econ; 2012; 15(4):695-703. PubMed ID: 22397590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral anticoagulation strategies after a first idiopathic venous thromboembolic event.
    Aujesky D; Smith KJ; Roberts MS
    Am J Med; 2005 Jun; 118(6):625-35. PubMed ID: 15922694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of self-managed versus physician-managed oral anticoagulation therapy.
    Regier DA; Sunderji R; Lynd LD; Gin K; Marra CA
    CMAJ; 2006 Jun; 174(13):1847-52. PubMed ID: 16785459
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genotype-guided dosing of vitamin K antagonists.
    Cavallari LH; Kittles RA; Perera MA
    N Engl J Med; 2014 May; 370(18):1763. PubMed ID: 24785218
    [No Abstract]   [Full Text] [Related]  

  • 36. Genotype-guided dosing of vitamin K antagonists.
    Koller EA; Roche JC; Rollins JA
    N Engl J Med; 2014 May; 370(18):1761. PubMed ID: 24785214
    [No Abstract]   [Full Text] [Related]  

  • 37. Genotype-guided dosing of vitamin K antagonists.
    Kimmel SE; French B; Geller NL;
    N Engl J Med; 2014 May; 370(18):1763-4. PubMed ID: 24785213
    [No Abstract]   [Full Text] [Related]  

  • 38. Cost-effectiveness of dronedarone in atrial fibrillation: results for Canada, Italy, Sweden, and Switzerland.
    Åkerborg Ö; Nilsson J; Bascle S; Lindgren P; Reynolds M
    Clin Ther; 2012 Aug; 34(8):1788-802. PubMed ID: 22770643
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation.
    Shah SV; Gage BF
    Circulation; 2011 Jun; 123(22):2562-70. PubMed ID: 21606397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genotype-guided dosing of vitamin K antagonists.
    Pirmohamed M; Wadelius M; Kamali F;
    N Engl J Med; 2014 May; 370(18):1764-5. PubMed ID: 24804303
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.